QPI-1002: Phase III started

SBI’s Quark Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, international Phase III ReGIFT trial to evaluate single doses of IV QPI-1002 in about 634 patients. Quark grant...